Difference between revisions of "Abiraterone (Zytiga)"
| Line 6: | Line 6: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.zytiga.com/downloads/full_product_information.pdf#page=5 Abiraterone (Zytiga) package insert PDF pages 5-6]<ref>[http://www.zytiga.com/downloads/full_product_information.pdf#page=5 Abiraterone (Zytiga) patient information on package insert PDF pages 5-6]</ref> | ||
*[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 17:26, 1 March 2012
FDA approved 4/28/2011
General information
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Abiraterone (Zytiga) package insert PDF pages 5-6[3]
- Abiraterone (Zytiga) patient drug information (UpToDate)[4]